NC
SLS icon

NewSquare Capital’s SELLAS Life Sciences SLS Stock Holding History

NewSquare Capital’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-100
Closed -$157 – 858
2023
Q2 		$157 Hold
100
– – ﹤0.01% 773
2023
Q1 		$143 Hold
100
– – ﹤0.01% 810
2022
Q4 		$236 Buy
+100
New +$280 ﹤0.01% 720

Other funds holding SLS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EH
Equitable Holdings New York $16.7B AUM 24.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
OCG
Opus Capital Group Cincinnati, Ohio $1.03B AUM 20.67% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

NewSquare Capital's SLS Position: Q3 2023 in Review

NewSquare Capital sold out of SELLAS Life Sciences (SLS) in Q3 2023, closing a stake of 100 shares — an estimated $157 sold.

NewSquare Capital first reported a position in SLS in Q4 2022 and held it in 3 quarters. The position peaked at $236 in Q4 2022. 28 funds tracked by Wall St. Rank hold SLS as of Q3 2023.

  • NewSquare Capital reported no remaining SELLAS Life Sciences position as of Q3 2023 after selling out during the quarter.
  • NewSquare Capital sold 100 SELLAS Life Sciences shares in Q3 2023, an estimated $157.
  • NewSquare Capital first reported a position in SELLAS Life Sciences in Q4 2022 and held it in 3 quarters.
  • NewSquare Capital's SELLAS Life Sciences position peaked at $236 in Q4 2022.
  • 28 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.